Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

688321 Shenzhen Chipscreen Biosciences

21.830
+0.080+0.37%
Market Close 09/29 15:00 CCT
High
22.440
Open
21.880
Turnover
39.47M
Low
21.770
Pre Close
21.750
Volume
17.85K
Market Cap
8.97B
P/E(TTM)
909.58
52wk High
42.470
Shares
410.72M
P/E(Static)
411.89
52wk Low
20.300
Float Cap
8.97B
Bid/Ask %
34.10%
Historical High
125.000
Shs Float
410.72M
Volume Ratio
1.17
Historical Low
20.300
Dividend TTM
--
Div Yield TTM
--
P/B
6.33
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.44%
Amplitude
3.08%
Avg Price
22.107
Lot Size
100
Float Cap
8.97B
Bid/Ask %
34.10%
Historical High
125.000
Shs Float
410.72M
Volume Ratio
1.17
Historical Low
20.300
Dividend TTM
--
Limit Up
26.100
P/B
6.33
Dividend LFY
--
Limit Down
17.400
Turnover Ratio
0.44%
Amplitude
3.08%
Avg Price
22.107
Lot Size
100
Ask
7.45Klots
Bid
10.36Klots
Price Forecast

No Data

News

Comment

Company Overview More
The company is a modern biomedical enterprise founded by the senior homecoming team in the United States in 2001. The company specializes in the original innovative molecular entity drug research and development, and is committed to providing patients with affordable, clinically needed, revolutionary and innovative mechanism drugs. The company's main products are independent research and development of new molecular entities and novel mechanisms of the original new drugs. Including the national class 1 original drug cedarbamide (trade name "Epesa / Epidaza"), which is the first subtype selective histone deacetylase (HDAC) inhibitor in the world, and the national class 1 original drug ciglitazide, which has completed the phase III clinical trial, is the first PPAR full agonist to complete the phase III clinical trial in the world. The national class 1 original drug sioronil, which has carried out several II phase clinical trials of indications, is a multi-target and multi-pathway selective kinase inhibitor with novel mechanism. Corporate Honors: 2019 Guangdong-Hong Kong-Macau Greater Bay Area Annual meeting of listed companies and Corporate Social responsibility Summit "Outstanding" title, pharmaceutical industry proud enterprise on the 70th anniversary of the founding of New China, top 20 leading biotechnology enterprises in Shenzhen in 2019, etc.
CEO: XIANPING LU
Market: --
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...